Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Atara Biotherap
(NQ:
ATRA
)
0.6933
-0.0167 (-2.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Atara Biotherap
< Previous
1
2
3
4
5
Next >
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference
January 10, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 07, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension
January 06, 2022
From
Be The Match BioTherapies
Via
Business Wire
Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
December 13, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021
December 09, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
November 30, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences
November 08, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 05, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data
November 04, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress
November 04, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
October 28, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021
October 13, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
October 04, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 01, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021
September 29, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
September 27, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 03, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
September 02, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress
August 09, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors
August 09, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
August 02, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 02, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers
July 01, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect
June 07, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 04, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 14, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit
May 13, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.